Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Vanlev “approvable”

Executive Summary

Bristol-Myers Squibb must conduct "at least" one additional Vanlev trial in patients resistant to "multiple other antihypertensives used in combination at their highest tolerated doses," FDA says in deeming Vanlev "approvable." The request follows recommendations made by FDA's Cardiovascular & Renal Drugs Advisory Committee after Vanlev benefits were not found to outweigh risks of angioedema. Members recommended that the length of the additional study be 24 weeks, but FDA indicated that eight weeks could be sufficient (1"The Pink Sheet" July 22, p. 20). Bristol resubmitted the omapatrilat NDA in December 2001 after pulling it in April 2000...
Advertisement

Related Content

Merck R&D head passes the baton
Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS040640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel